Impact of Significant Hemoglobin Drop without Bleeding in Patients Undergoing Transcatheter Aortic Valve Replacement

Abstract

Background Hemoglobin (Hgb) drop without bleeding is common among patients undergoing transcatheter aortic valve replacement (TAVR); however, the clinical implications of significant Hgb drop have not been fully evaluated. We sought to describe clinical phenotype and outcomes of patients with significant Hgb drop without bleeding.

Methods Consecutive patients undergoing TAVR at our institution from 2011-2021 were retrospectively reviewed. Three groups were assessed: No Hgb Drop and No Bleed (NoD-NoB – reference group), Hgb Drop with Bleed (D-wB), and Hgb Drop and No Bleed (D-NoB). Hgb drop was defined as ≥3 g/dL decrease from pre-to post-TAVR. Outcomes of interest were in-hospital death and 1-year all-cause mortality.

Results A total of 1,851 cases with complete Hgb data were included: NoD-NoB: n=1,579 (85.3%); NoD-NoB: n=49 (2.6%); D-wB n=223 (12.6%). Compared to NoD-NoB, D-NoB were older (81.1 vs. 78.9 years) with higher pre-procedure Hgb (12.9 vs. 11.7 g/dL). In-hospital death rate was higher among patients with D-NoB vs. NoD-NoB (4.5% vs. 0.8%, p<0.001) and similar to D-wB (4.5% vs. 4.1%, p=0.999). Predictors of in-hospital death were D-NoB (odds ratio [OR]: 3.45; 95% confidence interval [CI]: 1.32-8.69) and transfusion (OR: 10.6; 95% CI 4.25-28.2). Landmark survival analysis found that D-NoB experienced one-year mortality rate comparable to NoD-NoB, while D-wB had higher mid-term mortality (HR: 3.2; 95% CI: 1.83-5.73), and transfusion continued to impact mortality (HR: 2.5; 95% CI 1.79-3.63).

Conclusion Hemoglobin drop without bleeding is common among patients undergoing TAVR and may represent a higher risk of peri-procedural death. Blood transfusion increases short-and mid-term mortality risk in patients with and without bleeding, supporting a restrictive transfusion strategy.

What Is Known; What the Study Adds What is Known

• - Hemoglobin drop without overt bleeding may be seen after transcatheter aortic valve replacement (TAVR); however, its incidence and impact on clinical outcomes is unknown.

What the Study Adds

• - Hemoglobin drop without a source of bleeding is not uncommon among patients undergoing TAVR.

• - Patients more likely to have hemoglobin drop without bleeding include those with lower body surface area, older age, and higher pre-procedural hemoglobin level.

• - Compared to patients without bleeding or hemoglobin drop, patients with hemoglobin drop without bleeding had higher inpatient mortality.

• - Blood transfusion increased short-and long-term mortality in patients with or without bleeding.

• Download figure
• Open in new tab

Competing Interest Statement

Toby Rogers ? Consultant: Edwards Lifesciences, Medtronic, Boston Scientific, Abbott; Advisory board: Medtronic, Boston Scientific; Equity: Transmural Systems; Intellectual property: co-inventor on patents, assigned to NIH. Hector M. Garcia-Garcia reports receiving institutional grants from Medtronic, Biotronik, Neovasc, Boston Scientific, Abbott, Shockwave, Chiesi, and Philips. Ron Waksman reports serving on the advisory boards of Abbott Vascular, Boston Scientific, Medtronic, Philips IGT, and Pi-Cardia Ltd.; being a consultant for Abbott Vascular, Biotronik, Boston Scientific, Cordis, Medtronic, Philips IGT, Pi-Cardia Ltd., Swiss Interventional Systems/SIS Medical AG, and Transmural Systems Inc.; receiving institutional grant support from Amgen, Biotronik, Boston Scientific, and Philips IGT; and being an investor in MedAlliance and Transmural Systems. All other authors ? None.

Clinical Trial

This study was not registered because it is a retrospective analysis of data from a single center included on the Transcatheter Valve Therapy (TVT) Registry.

Funding Statement

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This study was approved by the institutional review board at MedStar Washington Hospital Center.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes